Patents Represented by Attorney Adley F. Mandel
  • Patent number: 7666439
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
    Type: Grant
    Filed: August 21, 2006
    Date of Patent: February 23, 2010
    Assignee: Wyeth LLC
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Patent number: 7635481
    Abstract: The present invention provides a safe and effective vaccine composition which comprises: an effective immunizing amount of an inactivated Ehrlichia canis bacterin; a pharmacologically acceptable carrier; and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent. The present invention also provides a method for the prevention or amelioration of canine ehrlichiosis in dogs.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: December 22, 2009
    Assignee: Wyeth
    Inventors: Liangbiao (George) Hu, Thomas J. Hess, Yu-Wei Chiang, Hsien-Jue (Steve) Chu
  • Patent number: 7622124
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: November 24, 2009
    Assignee: Wyeth
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Patent number: 7575752
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: August 18, 2009
    Assignees: Virginia Tech Intellectual Properties, Inc., Iowa State University Research Foundation, Inc.
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Patent number: 7345152
    Abstract: The present invention provides a monoclonal antibody specific for an epitope which is unique to the surface protein component of an inactivated feline immunodeficiency virus (FIV) envelope glycoprotein. Said antibody is useful for the quantification of inactivated FIV or the determination of the potency of an inactivated FIV vaccine.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: March 18, 2008
    Assignee: Wyeth
    Inventor: Chengjin M. Huang
  • Patent number: 7306807
    Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: December 11, 2007
    Assignee: Wyeth
    Inventors: Chengjin Huang, Jennifer Hess
  • Patent number: 7279166
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: October 9, 2007
    Assignees: Virginia Tech Intellectual Properties, Inc., Iowa State University Research Foundation, Inc.
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Patent number: 7276353
    Abstract: The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: October 2, 2007
    Assignees: Virginia Tech Intellectual Properties, Inc., Iowa State University Research Foundation, Inc.
    Inventors: Xiang-Jin Meng, Martijn Fenaux, Patrick G. Halbur
  • Patent number: 7169398
    Abstract: The present invention provides an immunogenically active component comprising inactivated Sarcocystis neurona cells and/or inactivated Neospora hughesi cells; antigens derived therefrom; DNA derived therefrom; or a mixture; or in combination with other vaccine components; thereof. Further provided are vaccine compositions useful for preventing or ameliorating equine protozoal myeloencephalitis infection and disease and a method for the cell culture propagation of protozoan parasites.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: January 30, 2007
    Assignee: Wyeth
    Inventors: Rocky Barry Bigbie, Terry Kaleung Ng, Joseph Wilson Whalen, Jr.
  • Patent number: 7169394
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: January 30, 2007
    Assignee: Wyeth
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Patent number: 7018638
    Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polyoxypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: March 28, 2006
    Assignee: Wyeth
    Inventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
  • Patent number: 6610310
    Abstract: Mucosal adjuvants for vaccines contain water-soluble polyanionic polymers which have anionic constitutional units obtained from acids such as acrylic acid, methacrylic acid, maleic acid, fumaric acid, ethylsulphonic acid, vinylsulphuric acid, vinylsulphonic acid, styrenesulphonic acid, vinylphenylsulphuric acid, 2-methacryloyloxyethane sulphonic acid, 3-methacryloyloxy-2-hydroxypropanesulphonic acid, 3-methacryl amido-3-methylbutanoic acid, acrylamidomethylpropanesulphonic acid, vinylphosphoric acid, 4-vinylbenzoic acid, 3-vinyl oxypropane-1-sulphonic acid, N-vinylsuccinimidic acid, and salts of the foregoing. The polyanionic polymers may further have hydrophobic constitutional repeating units, such as alkylesters, cycloalkylesters, hydroxyalkylesters, ethers, glycols, aromatic groups and salts thereof. The adjuvants containing the polyanionic polymers are used in vaccines for the induction or enhancement of mucosal immune responses.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: August 26, 2003
    Assignee: American Cyanamid Company
    Inventor: Luuk Hilgers
  • Patent number: 6524592
    Abstract: The invention relates to vaccines which are suitable for the prevention of clostridial diseases of sheep (and lambs), providing an effective immunity for up to a year or more following a single injection or dose.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: February 25, 2003
    Assignee: American Home Products Corporation
    Inventors: Richard Buchta, Christopher Leigh Schwartzkoff, Philip Ralph Lehrbach
  • Patent number: 5422122
    Abstract: A pharmaceutical dosage form is prepared from a multiplicity of coated potassium chloride crystals coated with two distinct layers, the first of ethylcellulose and the second of a hydrophilic coating polymer, preferably hydroxypropylcellulose, resulting in microcapsules. These microcapsules are capable of being compressed into tablets of suitable hardness and friability with minimum quantities of excipients. The resultant controlled release tablets are useful for treatment of potassium deficiencies in humans.
    Type: Grant
    Filed: August 4, 1992
    Date of Patent: June 6, 1995
    Assignee: Eurand America, Incorporated
    Inventor: Thomas C. Powell
  • Patent number: 5306506
    Abstract: The invention provides a solid pharmaceutical composition for addition to water to produce a suspension of a drug comprising (a) a drug which is substantially water-insoluble or microencapsulated; (b) a thickening or suspending agent; (c) a pharmaceutically acceptable acid; (d) a pharmaceutically acceptable carbonate or bicarbonate; characterised in that the weight ratio of c+d:b is from 1:1.5 to 1:15 and the amount of c+d is sufficient to obtain rapid hydration of the thickening or suspending agent (b) when the composition is mixed with water such that a homogeneous suspension of the drug is obtained within 30 seconds. A method for preparing the composition is also described.
    Type: Grant
    Filed: March 3, 1992
    Date of Patent: April 26, 1994
    Assignee: Eurand International S.p.A.
    Inventors: Marco Zema, Luigi G. Mapelli, Marco G. Marconi
  • Patent number: 5196149
    Abstract: This disclosure is directed to a high solid, low viscosity carbonless paper gelatin base microcapsule system producing microcapsules having sizes characteristically from about 3 to about 10 microns (micrometers) and being characterized as single oil drop microcapsules. This system of microcapsules is further characterized by a high solids content, viz., from about 25 to about 50 weight percent solids, in combination with a low viscosity, viz., ranging from about 10 to about 60 centipoises and having a high microcapsule payload (core concentration by weight based on total capsule weight), e.g., of 80+wt. % and preferbly about 90 weight percent and higher, in aqueous suspensions. The combination of high solid content and high microcapsule payload, with low viscosity enables delivery of a high concentration of solid microcapsules at reasonably high coating speeds via comparatively inexpensive conventional pumping systems and paper coating systems.
    Type: Grant
    Filed: June 26, 1991
    Date of Patent: March 23, 1993
    Assignee: Eurand America, Inc.
    Inventor: Joseph A. Scarpelli
  • Patent number: 5095151
    Abstract: There is described a process for the preparation of high yields of propranolol hydrochloride having a particle size within the range of 420 to 1200 microns wherein the propanolol hydrochloride is recrystallized from, as a solvent, a mixture of n-propanol and heptane.The propranolol hydrochloride macrocrystals are useful themselves in capsule pharmaceutical dosage forms and when coated with a sustained release coating composition, are useful in the manufacture of sustained action capsule and tablet pharmaceutical dosage.
    Type: Grant
    Filed: May 21, 1985
    Date of Patent: March 10, 1992
    Assignee: American Home Products Corporation
    Inventors: Paul C. Guley, James S. Farina
  • Patent number: 5047238
    Abstract: An efficacious parenterally administered inactivated canine coronavirus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent canine coronavirus is produced. A method for propagation of the canine coronavirus and its attenuation and a method of evaluating the effectiveness of a canine coronavirus vaccine in canines is also disclosed.
    Type: Grant
    Filed: March 24, 1988
    Date of Patent: September 10, 1991
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, Bobby Edwards, John W. Black
  • Patent number: 5013663
    Abstract: An efficacious parenterally administered modified live Canine Corona virus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent Canine Corona virus is produced. A method for propagation of the Canine Corona virus and its attenuation and a method of evaluating the effectiveness of a Canine Corona virus vaccine in canines is also disclosed.
    Type: Grant
    Filed: March 24, 1989
    Date of Patent: May 7, 1991
    Assignee: American Home Products Corporation
    Inventors: William M. Acree, John W. Black
  • Patent number: 4933184
    Abstract: Disclosed herein are compositions and methods for enhancing the transdermal delivery of physiologically active agents across mammalian skin or membranes and which comprise a percutaneous transfer enhancing amount of menthol and a drug.
    Type: Grant
    Filed: April 3, 1987
    Date of Patent: June 12, 1990
    Assignee: American Home Products Corp. (Del)
    Inventor: Andrew G. Tsuk